185 related articles for article (PubMed ID: 28599401)
21. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
[TBL] [Abstract][Full Text] [Related]
22. Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study.
De Paola L; Coppolino G; Bolignano D; Buemi M; Lombardi L
Ther Apher Dial; 2010 Dec; 14(6):566-71. PubMed ID: 21118364
[TBL] [Abstract][Full Text] [Related]
23. Bone Fragility Fractures in CKD Patients.
Pimentel A; Ureña-Torres P; Bover J; Luis Fernandez-Martín J; Cohen-Solal M
Calcif Tissue Int; 2021 Apr; 108(4):539-550. PubMed ID: 33219822
[TBL] [Abstract][Full Text] [Related]
24. Osteoporosis and adynamic bone in chronic kidney disease.
Cannata-Andía JB; Rodriguez García M; Gómez Alonso C
J Nephrol; 2013; 26(1):73-80. PubMed ID: 23023723
[TBL] [Abstract][Full Text] [Related]
25. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
26. The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: a two-year prospective multicenter cohort study.
Przedlacki J; Buczyńska-Chyl J; Koźmiński P; Niemczyk E; Wojtaszek E; Gieglis E; Żebrowski P; Podgórzak A; Wściślak J; Wieliczko M; Matuszkiewicz-Rowińska J;
Osteoporos Int; 2018 May; 29(5):1105-1115. PubMed ID: 29411069
[TBL] [Abstract][Full Text] [Related]
27. Predictors of bone fractures in a single-centre cohort of hemodialysis patients: a 2-year follow-up study.
Brunerová L; Lažanská R; Kasalický P; Verešová J; Potočková J; Fialová A; Rychlík I
Int Urol Nephrol; 2018 Sep; 50(9):1721-1728. PubMed ID: 30117013
[TBL] [Abstract][Full Text] [Related]
28. Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study.
Haarhaus M; Monier-Faugere MC; Magnusson P; Malluche HH
Am J Kidney Dis; 2015 Jul; 66(1):99-105. PubMed ID: 25843703
[TBL] [Abstract][Full Text] [Related]
29. Does PTH offer additive value to ALP measurement in assessing CKD-MBD?
Lamb EJ; Delaney MP
Perit Dial Int; 2014; 34(7):687-91. PubMed ID: 25520480
[No Abstract] [Full Text] [Related]
30. Determination of NF-κB and RANKL levels in peripheral blood osteoclast precursor cells in chronic kidney disease patients.
Güneş G; Doğruer Ünal N; Eskandari G; Kiykim A; Bölgen Çimen Ö; Temel G; Çimen MBY
Int Urol Nephrol; 2018 Jun; 50(6):1181-1188. PubMed ID: 29644525
[TBL] [Abstract][Full Text] [Related]
31. Parathyroid hormone and biochemical profile in chronic kidney disease patients in South India.
Sankarasubbaiyan S; Abraham G; Soundararajan P; Chandrasekaran V; Padma G
Hemodial Int; 2005 Jan; 9(1):63-7. PubMed ID: 16191055
[TBL] [Abstract][Full Text] [Related]
32. Uremic Toxicity and Bone in CKD.
Yamamoto S; Fukagawa M
J Nephrol; 2017 Oct; 30(5):623-627. PubMed ID: 28573386
[TBL] [Abstract][Full Text] [Related]
33. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.
Danese MD; Kim J; Doan QV; Dylan M; Griffiths R; Chertow GM
Am J Kidney Dis; 2006 Jan; 47(1):149-56. PubMed ID: 16377396
[TBL] [Abstract][Full Text] [Related]
34. Elevated bone aluminum and suppressed parathyroid hormone levels in hypercalcemic dialysis patients.
Piraino B; Chen T; Puschett JB
Am J Nephrol; 1989; 9(3):190-7. PubMed ID: 2757078
[TBL] [Abstract][Full Text] [Related]
35. Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease: a cross-sectional study.
Jørgensen HS; Winther S; Bøttcher M; Hauge EM; Rejnmark L; Svensson M; Ivarsen P
BMC Nephrol; 2017 Sep; 18(1):284. PubMed ID: 28874132
[TBL] [Abstract][Full Text] [Related]
36. Reducing the risk of re-fracture in the dialysis population: is it time to consider therapy with PTH analogues?
Jamal SA; Hodsman AB
Semin Dial; 2011; 24(1):12-5. PubMed ID: 21299630
[TBL] [Abstract][Full Text] [Related]
37. Adverse Consequences of Chronic Kidney Disease on Bone Health in Children.
Kumar J; Perwad F
Semin Nephrol; 2021 Sep; 41(5):439-445. PubMed ID: 34916005
[TBL] [Abstract][Full Text] [Related]
38. How to predict and treat increased fracture risk in chronic kidney disease.
West SL; Patel P; Jamal SA
J Intern Med; 2015 Jul; 278(1):19-28. PubMed ID: 25758353
[TBL] [Abstract][Full Text] [Related]
39. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients.
Dogan E; Erkoc R; Sayarlioglu H; Soyoral Y; Dulger H
Ren Fail; 2008; 30(4):407-10. PubMed ID: 18569914
[TBL] [Abstract][Full Text] [Related]
40. Determination of bone architecture and strength in men and women with stage 5 chronic kidney disease.
West SL; Jamal SA
Semin Dial; 2012 Jul; 25(4):397-402. PubMed ID: 22686655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
